Search

everythinglearnresearchcommunity

for

Search:↓

Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

Formononetin may help protect the brain and treat neurological diseases.

Frontal fibrosing alopecia can occur in children, not just postmenopausal women.

The patient improved after antiviral treatment for a viral infection.

Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.

Venlafaxine may cause paranoid delusions in some patients.

The FDA rejected a testosterone drug again due to safety concerns.

Using tazarotene with GliSODin improves facial skin more than tazarotene alone.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Finasteride may help treat frontal fibrosing alopecia, but more research is needed.

Congenital triangular alopecia and vitiligo can occur together, but treatment for one may not affect the other.

Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.

Clofazimine effectively treated ashy dermatosis in a patient.

A new microneedle patch effectively promotes hair regrowth with less frequent dosing.

Microinfusion of methotrexate can help treat frontal fibrosing alopecia.

The new drug delivery system effectively targets lung cancer cells.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.